This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know
by Zacks Equity Research
ENTX stock jumps 35% in a month after the FDA backs a streamlined phase III plan for oral osteoporosis candidate EB613, bringing a key regulatory milestone into focus.
ENTXPositive Net Change LLYNegative Net Change NBIXNegative Net Change LQDAPositive Net Change
biotechnology biotechs medical pharmaceuticals
HALO Inks Deal With INCY to Support Cancer Therapy Development
by Zacks Equity Research
Halozyme grants ENHANZE rights to Incyte for developing subcutaneous cancer therapy formulations, aiming to improve treatment convenience for patients.
INCYNegative Net Change HALONegative Net Change RHHBYPositive Net Change JNJPositive Net Change
biotechs
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
by Ekta Bagri
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
MYGNNegative Net Change WVENegative Net Change SANANegative Net Change ILMNNegative Net Change NTLANegative Net Change CRSPNegative Net Change
biotechnology biotechs cell-therapy gene-editing gene-therapy genomics pharmaceuticals
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
by Zacks Equity Research
Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.
ZNTLNegative Net Change NBIXNegative Net Change AMRNNegative Net Change LQDAPositive Net Change
biotechs
Does EU Approval of Wegovy Pill Change NVO's Competitive Story?
by Ahan Chakraborty
Novo Nordisk wins EU approval for the first GLP-1 obesity tablet, expanding Wegovy's reach, but tougher competition keeps the broader investment outlook in focus.
NVONegative Net Change LLYNegative Net Change VKTXNegative Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix
by Ekta Bagri
QURE is sharpening its gene therapy focus through faster regulatory pathways, a streamlined business model and CNS pipeline expansion, with AMT-130 at the center.
QUREPositive Net Change SRPTNegative Net Change PTCTNegative Net Change
biotechnology biotechs pharmaceuticals
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?
by Ekta Bagri
QURE has soared on renewed AMT-130 optimism, but rich valuation, uneven earnings and pending regulatory milestones keep the gene therapy story balanced.
QUREPositive Net Change RHHBYPositive Net Change PTCTNegative Net Change WVENegative Net Change
biotechs medical pharmaceuticals
QURE Stock Outlook Rests on AMT-130, FDA Talks, and Cash Runway
by Ekta Bagri
QURE's AMT-130 is driving investor focus as FDA feedback, a targeted third-quarter 2026 filing and cash into 2029 shape its regulatory outlook.
QUREPositive Net Change PTCTNegative Net Change WVENegative Net Change
biotechs medical pharmaceuticals
HRMY Posts Preliminary Q2 Revenues, Announces CFO Transition
by Zacks Equity Research
Harmony Biosciences posts preliminary Q2 2026 Wakix revenues of about $261M, up 30% year over year, while reaffirming full-year guidance despite a CFO transition.
HRMYNegative Net Change NVAXNegative Net Change LQDAPositive Net Change
biotechnology biotechs pharmaceuticals
Can Novartis' Fabhalta Strengthen Its Nephrology Franchise?
by Ekta Bagri
NVS wins full FDA approval for Fabhalta in IgA nephropathy after phase III data shows slower kidney function decline, strengthening its nephrology portfolio.
NVSNegative Net Change VRTXNegative Net Change TVTXNegative Net Change
biotechnology biotechs medical pharmaceuticals